Abstract: The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
Type:
Grant
Filed:
June 7, 2000
Date of Patent:
December 23, 2003
Assignee:
Center for Molecular Medicine and Immunology
Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
Type:
Application
Filed:
February 14, 2003
Publication date:
December 11, 2003
Applicant:
Center for Molecular Medicine and Immunology
Abstract: The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.
Type:
Grant
Filed:
January 14, 2000
Date of Patent:
November 18, 2003
Assignee:
Center for Molecular Medicine and Immunology
Inventors:
Rosalyn D. Blumenthal, Walter Lew, Malik Juweid, Rita Alisauskas, Zhiliang Ying, David M. Goldenberg
Abstract: Kidney uptake of antibody fragment conjugates and protein conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof.
Type:
Application
Filed:
May 15, 2003
Publication date:
October 30, 2003
Applicant:
Center for Molecular Medicine an Immunology
Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
Type:
Grant
Filed:
March 24, 2000
Date of Patent:
April 1, 2003
Assignee:
Center for Molecular Medicine and Immunology
Abstract: Kits for detecting and treating endometriosis are provided, which contain a targeting molecule comprising an eosinophil peroxidase-binding component. Methods of detecting and treating endometriosis using eosinophil peroxidase-specific targeting molecules are also provided Targeting molecules comprise an eosinophil peroxidase-binding component and an accessory component; the accessory component comprising an agent conferring detectability or a therapeutic effect.
Type:
Grant
Filed:
March 31, 2000
Date of Patent:
April 1, 2003
Assignee:
Center for Molecular Medicine and Immunology
Inventors:
Rosalyn D. Blumenthal, David M. Goldenberg, Michael Samoszuk
Abstract: Kidney uptake of antibody fragment conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof.
Type:
Grant
Filed:
March 21, 1995
Date of Patent:
December 1, 1998
Assignee:
Center for Molecular Medicine and Immunology
Abstract: A conjugate of a tumor cell-targeting protein or polypeptide and a nucleic acid-targeting small molecule labeled with an Auger electron-emitting radionuclide is useful for tumor therapy. The tumor cell-targeting protein or polypeptide may be an antibody or fragment thereof, a hormone or a growth factor.
Type:
Grant
Filed:
August 1, 1996
Date of Patent:
June 2, 1998
Assignee:
Center For Molecular Medicine and Immunology
Abstract: The present invention relates to conjugates of diagnostic or therapeutic principles, such as drugs, toxins, chelators, boron compounds and detectable labels, to an antibody, in which the diagnostic or therapeutic principle is first loaded onto a polymer carrier such as an aminodextran or a polypeptide of at least 50 amino acids in length, and this intermediate is in turn site-specifically conjugated to a targeting antibody such as an antitumor antibody. The resultant conjugate substantially retains the immunoreactivity of the antibody, and targets the diagnostic or therapeutic principle to a target tissue or organ where the diagnostic or therapeutic effect is realized.
Type:
Grant
Filed:
August 23, 1988
Date of Patent:
October 15, 1991
Assignee:
The Center for Molecular Medicine and Immunology
Inventors:
Lisa B. Shih, Frederick J. Primus, Milton D. Goldenberg
Abstract: Antibodies and antibody conjugates which have been modified by conjugation to, or exposure thereon, of glycoside residues that bind to the human hepatic asialoglycoprotein receptor clear rapidly from the circulation. Use of such modified antibodies and antibody conjugates for imaging and therapy of tumors and infectious lesions is advantageous when the antibodies are administered by a regional route, or when intravenous administration is accompanied by injection of a competitive hepatic lectin binding inhibitor to control the rate of clearance and optimize uptake by the target tissues.
Type:
Grant
Filed:
September 14, 1987
Date of Patent:
August 22, 1989
Assignee:
Center for Molecular Medicine and Immunology
Abstract: An improved method of dual isotope subtraction scintigraphic image processing uses a band pass spatial frequency filter to smooth and enhance the image obtained with the less well resolved isotope and then applies the same filter function to the image from the better resolved isotope, after which the images are subtracted to produce an enhanced image with reduced edge artifacts and better resolution. The method can be applied to images where the target/background ratio approaches unity, and to single isotope imaging.
Type:
Grant
Filed:
December 1, 1987
Date of Patent:
July 11, 1989
Assignee:
The Center for Molecular Medicine and Immunology
Abstract: A conjugate of methotrexate to an antibody is prepared by loading methotrexate onto an aminodextran, then specifically conjugating the polymer carrier to the carbohydrate portion of an antitumor antibody, using a reduced Schiff base linkage. The conjugate is useful for tumor targeted therapy.
Type:
Grant
Filed:
February 25, 1986
Date of Patent:
October 13, 1987
Assignee:
Center for Molecular Medicine & Immunology
Inventors:
Lisa B. Shih, Frederick J. Primus, Milton D. Goldenberg